Company: DVAX
Filing Date: 2025-04-22
Form Type: DFAN14A
Source: 0001193125-25-087436
Chunk: 4

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-22
Form: DFAN14A
Chunk 4
---
 highly qualified nominees: |

| • |     | Brett Erkman: a Managing Director at Deep Track Capital. Mr. Erkman has spent the last twenty years                               
 investing in biotechnology companies and will bring a much needed (and the only) perspective of a large shareholder to the Board. |

| • |     | Jeffrey Farrow: the Chief Financial Officer at Tarsus Pharmaceuticals (NASDAQ: TARS). Mr. Farrow was                                                                                                                                                      
 also the CFO at Global Blood Therapeutics, Inc. (formerly NASDAQ: GBT; sold to Pfizer for $5.4 billion), ZS Pharma, Inc. (formerly NASDAQ: ZSPH; sold to AstraZeneca for $2.7 billion), and Hyperion Therapeutics (formerly NASDAQ: HPTX; sold to Horizon 
 Pharma plc for $1.1 billion).                                                                                                                                                                                                                             |

| • |     | Michael Mullette: the interim Chief Executive Officer at Lykos Therapeutics. Mr. Mullette was 
 previously the Vice President of North American Commercial Operations at Moderna, Inc.        |

3

| (NASDAQ: MRNA) and spent nearly twenty years at Sanofi (NASDAQ: SNY) in a variety of positions including senior roles in global commercial operations. |

| • |     | Donald Santel: the former President and Chief Executive Officer of Hyperion Therapeutics (formerly NASDAQ:                                                                                                                                    
 HPTX), which developed and brought Ravicti to market for urea cycle disorders and was ultimately acquired by Horizon Pharma in 2015. Prior to Hyperion, Mr. Santel was the Chief Executive Officer of CoTherix (formerly NASDAQ: CTRX), which 
 developed Ventavis for pulmonary arterial hypertension and was acquired by Actelion in 2006.                                                                                                                                                  |

*** This year’s Annual Meeting offers an important chance to make your voice heard. Do not let the Dynavax Board continue to ignore your best interests. Regards, David Kroin Founder and Chief Investment Officer, Deep Track Capital LP 4

EVERY VOTE MATTERS

Your vote is important, no matter how many shares of Common Stock you own. We urge you to follow the instructions set forth on the enclosed
proxy card to vote via the Internet or by telephone or to mark, sign, date, and return the enclosed proxy card by mail today to vote the election of the four Deep Track Nominees and in accordance with the Deep
Track Parties’ recommendations on the other proposals on the agenda for